PMID- 28730764
OWN - NLM
STAT- MEDLINE
DCOM- 20190712
LR  - 20211204
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 22
IP  - 3
DP  - 2017 May-Jun
TI  - mTOR deregulation in oral cavity squamous cell carcinoma.
PG  - 610-613
AB  - Signal transduction pathways consist of a variety of inter- and intra-cellular 
      molecules. They act as supporting mechanisms for cell survival and homeostasis. 
      Among them, the phosphatidylinositol 3-kinase (PI3K)/tumor suppressor phosphatase 
      and tensin homologue deleted on chromosome ten (PTEN)/protein kinase B 
      (Akt)/mammalian target of rapamycin (mTOR) pathway plays a crucial role in 
      regulating normal cell growth based on growth factor receptors (GFRs) 
      interaction, including epidermal GFR (type II-HER2) and insulin GFR (IGF). mTOR 
      protein acts as a serine-threonine kinase that belongs to the PI3K-related kinase 
      family. It mediates protein and lipid synthesis, mitochondrial metabolism, 
      biogenesis, proliferation and also negatively regulates autophagy. Two distinct 
      multiprotein complexes have been mainly identified and cloned: mTOR complex 1 
      (mTORC1) and mTOR complex 2 (mTORC2). mTOR is deregulated predominantly due to 
      mutations, deletions, loss of heterozygosity (LOH) or abnormal phosphorylation of 
      the upstream molecules inside the current pathway. Pure mTOR mutations are very 
      rare. Development of specific inhibitors at the basis of targeted therapeutic 
      strategies such as rapamycin (rapalogs) is an evolution in handling patients with 
      mTOR abnormal overactivity. In the current special article we explored the role 
      of the gene deregulation leading to abnormal protein expression in oral cavity 
      squamous cell carcinoma (SCC).
FAU - Mastronikolis, Nicholas S
AU  - Mastronikolis NS
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical School, 
      University of Patras, Patras, Greece.
FAU - Tsiambas, Evangelos
AU  - Tsiambas E
FAU - Papadas, Theodoros A
AU  - Papadas TA
FAU - Fotiades, Panagiotis P
AU  - Fotiades PP
FAU - Papadas, Athanasios T
AU  - Papadas AT
FAU - Mastronikolis, Stylianos N
AU  - Mastronikolis SN
FAU - Kastanioudakis, Ioannis
AU  - Kastanioudakis I
FAU - Ragos, Vasileios
AU  - Ragos V
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Benzamides)
RN  - 0 (Morpholines)
RN  - 0 (Pyrimidines)
RN  - 0BSC3P4H5X (vistusertib)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Benzamides
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 2/physiology
MH  - Morpholines/therapeutic use
MH  - Mouth Neoplasms/*metabolism
MH  - Mutation
MH  - PTEN Phosphohydrolase/physiology
MH  - Pyrimidines
MH  - Signal Transduction/physiology
MH  - Squamous Cell Carcinoma of Head and Neck/*metabolism
MH  - TOR Serine-Threonine Kinases/*genetics/physiology
EDAT- 2017/07/22 06:00
MHDA- 2019/07/13 06:00
CRDT- 2017/07/22 06:00
PHST- 2017/07/22 06:00 [entrez]
PHST- 2017/07/22 06:00 [pubmed]
PHST- 2019/07/13 06:00 [medline]
PST - ppublish
SO  - J BUON. 2017 May-Jun;22(3):610-613.